In high-grade serous ovarian cancer (HGSOC), the overexpression of the gain-of-function p53 mutation (p53R248Q) may impact EGFR-related signaling and the resulting medication inhibition effect. Under EGFR/MDM2-targeted inhibition, the R248Q mutation of p53 in HGSOC resulted in notable alterations in signaling protein activity and trafficking. The gene discussed is EGFR; the disease is ovarian serous adenocarcinoma.